STOCK TITAN
  1. Home
  2. News
  3. CKPT

Checkpoint Therapeutics Inc - CKPT STOCK NEWS

Welcome to our dedicated news page for Checkpoint Therapeutics (Ticker: CKPT), a resource for investors and traders seeking the latest updates and insights on Checkpoint Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Checkpoint Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Checkpoint Therapeutics's position in the market.

News
Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Checkpoint Therapeutics, Inc. announces financial results for full-year 2023 and corporate updates. The company plans to resubmit a Biologics License Application for cosibelimab by mid-year for potential approval before 2024 end. Checkpoint remains confident in the clinical data and safety package.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.11%
Tags
earnings
-
News
Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors
Rhea-AI Summary
Checkpoint Therapeutics, Inc. appoints Dr. Amit Sharma as an independent director to its Board. Dr. Sharma brings extensive experience in clinical development and leadership roles from his tenure at Alexion and Bayer Pharmaceuticals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
management
-
News
Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market
Rhea-AI Summary
Checkpoint Therapeutics, Inc. has entered into an agreement for the issuance and sale of over 7.7 million shares of its common stock in a registered direct offering priced at-the-market. The company will also issue unregistered warrants to purchase additional shares. The offering is expected to raise significant capital for the company's clinical-stage immunotherapy and targeted oncology programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.45%
Tags
offering
News
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
Rhea-AI Summary
Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) announced that James Oliviero, President and CEO, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference on January 18, 2024, at 4:00 p.m. EST.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.05%
Tags
conferences
-
News
U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer
Rhea-AI Summary
FDA Raises No Concerns for XYZ Pharmaceuticals (Ticker: XYZ)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-44.88%
Tags
none
-
News
Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance
Rhea-AI Summary
Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) announced the issuance of a new patent by the USPTO covering a method of treating various cancers, including cSCC, through the administration of cosibelimab. This, along with a previously issued composition of matter patent, protects cosibelimab in the U.S. through at least May 2038. The company's BLA for cosibelimab is currently under FDA review, with a PDUFA goal date of January 3, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
News
Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
Rhea-AI Summary
Checkpoint Therapeutics, Inc. (CKPT) announces the review of the Biologics License Application for cosibelimab by the U.S. FDA, with a PDUFA goal date of January 3, 2024. Recent pivotal trial results for cosibelimab were published, further supporting its efficacy and safety. The company also reported longer-term data from its pivotal trials, demonstrating a deepening of response over time. Checkpoint's cash and cash equivalents totaled $1.8 million as of September 30, 2023, with net loss attributable to common stockholders for the third quarter of 2023 at $5.7 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.63%
Tags
earnings
-
News
Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer
Rhea-AI Summary
Checkpoint Therapeutics announces positive results from a trial evaluating cosibelimab in patients with metastatic cutaneous squamous cell carcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
none
-
News
Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds
Rhea-AI Summary
Checkpoint Therapeutics, Inc. announced the immediate exercise of certain outstanding warrants, expected to generate approximately $11.13 million in gross proceeds. The funds will be used for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.29%
Tags
none
News
Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference
Rhea-AI Summary
Checkpoint Therapeutics to participate in Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
conferences
Stock CKPT logo
Checkpoint Therapeutics Inc

Nasdaq:CKPT

CKPT Rankings

#4703 Ranked by Market Cap
#5323 Ranked by Stock Gains
N/A Ranked by Dividends

CKPT Stock Data

63.52M
28.74M
7.87%
14.53%
10.48%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About CKPT

checkpoint therapeutics, inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. the company's product candidates include ck-101 that in phase i clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and cosibelimab, a programmed death ligand-1 (pd-l1), which is in phase i clinical trial in patients with selected recurrent or metastatic cancers. it also develops ck-103, a small molecule inhibitor of bet bromodomains; and ck-302, a human agonistic antibody for oncology indications. checkpoint therapeutics, inc. has collaboration agreements with tg therapeutics, inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. the company was founded in 2014 and is headquartered in new york, new york. checkpoint therapeutics, inc. is a subsidiary of fortr